FULC
Fulcrum Therapeutics Inc
NASDAQ · Pharmaceuticals
$9.74
+0.19 (+1.99%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 85.15M | 52.88M | 380.48M | 366.88M | 363.96M |
| Net Income | -10,350,739 | -5,785,049 | 50.86M | 47.13M | 41.26M |
| EPS | — | — | — | — | — |
| Profit Margin | -12.2% | -11.6% | 13.4% | 12.9% | 11.3% |
| Rev Growth | +61.0% | +61.0% | -8.7% | +22.0% | +14.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 296.26M | 278.39M | 348.66M |
| Total Equity | — | — | 433.60M | 429.92M | 514.10M |
| D/E Ratio | — | — | 0.68 | 0.65 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -8,655,302 | -5,106,214 | 71.18M | 69.95M | 74.03M |
| Free Cash Flow | — | — | 46.38M | 54.75M | 38.77M |